Program
sumecigrel
Also written as “Vicagrel 6mg”, “Vicagrel” and “Vicagrel Capsules”.
Its studies are mostly in Acute Coronary Syndrome · Coronary Artery Disease, led by Jiangsu vcare pharmaceutical technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu vcare pharmaceutical technology | 81 open or running | phase 3since Aug 28, 2024 | Jul 9, 2018 | Dec 30, 2026phase 3 · NCT06577519 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 9, 2018First study: phase 2 study in Coronary Artery DiseaseFirst studyNCT03599284 · 279 enrolled · China
- Apr 24, 2019Phase 1 study in Healthy SubjectsNCT03942458 · 50 enrolled · China
- Oct 21, 2019Phase 1 study in Healthy Male AdultNCT04143750 · 6 enrolled · China
- Jun 8, 2021Phase 1 study in Acute Coronary SyndromeNCT04919551 · 24 enrolled · China
- Dec 14, 2021Phase 1 study in Acute Coronary SyndromeNCT05162053 · 128 enrolled · United States, China
- Nov 17, 2022Phase 1 study in Healthy SubjectsNCT05651074 · 20 enrolled · China
- Aug 28, 2024Phase 3 study in Acute Coronary SyndromeNCT06577519 · 1,000 planned · China
- Jul 7, 2025Phase 1 study in Acute Coronary SyndromeNCT07067775 · 18 enrolled · China
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Acute Coronary SyndromeNCT06577519
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07067775Acute Coronary Syndrome · China | 1 | Completed | Aug 22, 2025 | 18 |
| NCT06577519Acute Coronary Syndrome · China | 3 | Recruiting | Dec 30, 2026 | 1,000 |
| NCT05651074Healthy Subjects · China | 1 | UNKNOWN | Feb 2023 | 20 |
| NCT05162053Acute Coronary Syndrome · United States, China | 1 | Completed | Nov 3, 2022 | 128 |
| NCT04919551Acute Coronary Syndrome · China | 1 | Completed | Oct 20, 2021 | 24 |
| NCT04143750Healthy Male Adult · China | 1 | Completed | Dec 29, 2019 | 6 |
| NCT03942458Healthy Subjects · China | 1 | Completed | Jun 28, 2019 | 50 |
| NCT03599284Coronary Artery Disease · China | 2 | Completed | Jun 11, 2019 | 279 |
How it is read
Names in the registry
- “Vicagrel 6mg”, 2 entries
- “Vicagrel”, 1 entry
- “Vicagrel Capsules”, 1 entry
- “vicagrel Capsules”, 1 entry
- “Vicagrel and omeprazole”, 1 entry
Conditions, from the studies’ own filings
- Acute Coronary Syndrome, 4 studies
- Coronary Artery Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.